During the past decade, Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 3 clinical trials were completed, i.e. on average, 18.8% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 2 clinical trials were completed. i.e. 16.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine" #1 sponsor was "Janssen Research & Development, LLC" with 5 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "Poniard Pharmaceuticals" with 2 trials sponsored and "Active Biotech AB" with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine" #1 collaborator was "Astellas Pharma Inc" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator, "GOG Foundation" with 1 trials as a collaborator and "Johnson & Johnson Pharmaceutical Research & Development, L.L.C." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine" are "Prostate Cancer" (2 trials), "Alzheimer's Disease" (1 trials), "Anemia" (1 trials), "Breast Cancer" (1 trials) and "Bronchial Asthma" (1 trials). Many other conditions were trialed in "Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine" in a lesser frequency.

Most popular intervention types in "Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine" are "Drug" (21 trials), "Biological" (4 trials), "Other" (3 trials), "Device" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (3 trials), "Atezolizumab" (2 trials), "ABR-217620/naptumomab estafenatox" (1 trials), "Abemaciclib" (1 trials) and "Abiraterone acetate (AA)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine" are 13 trials for "All" genders, 6 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine". undefined are not yet recruiting, 7 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine, 2 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".